Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13096993 | 0.86 | MAOB (0.50) | MAOBALDH1A1MAOACYP4F2CYP4A11 | |
| SCHEMBL13097027 | 0.85 | MAOB (0.49) | MAOBALDH1A1MAOACYP4F2CYP4A11 | |
| SCHEMBL13097003 | 0.83 | CHRNB4 (0.48) | MAOBCYP2D6CNR1CNR2 | |
| SCHEMBL13097004 | 0.83 | CYP2D6 (0.44) | MAOBALDH1A1CYP2D6CNR1CNR2 | |
| SCHEMBL13107194 | 0.82 | ALDH1A1 (0.45) | ALDH1A1CYP2D6 | |
| SCHEMBL321181 | 0.81 | FOXM1 (0.59) | MAOBFOXM1MAOABCHE | |
| SCHEMBL13097038 | 0.80 | CYP2D6 (0.40) | MAOBCYP2D6CNR1CNR2 | |
| SCHEMBL9309282 | 0.79 | ALOX5 (0.48) | CYP2D6CYP4F2CYP4A11 | |
| SCHEMBL13097008 | 0.78 | MAOB (0.50) | MAOBALDH1A1MAOABCHE | |
| SCHEMBL9308680 | 0.78 | ALOX5 (0.52) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | MAOB 200/4885ALDH1A1 524/4885CYP2D6 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.